Abstract
Summary
The Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) treatment is expected to reach USD 2,249,032.64 thousand by 2030, from USD 966,456.13 thousand in 2022, growing at the CAGR of 11.6% in the forecast period of 2023 to 2030.
Market Segmentation
Asia-Pacific Acute Respiratory Distress Syndrome (Ards) Treatment Market, By Type (Mechanical Ventilation, Corticosteroids, Antiviral Medication, Extracorporeal Membrane Oxygenation (ECMO), Tocilizumab, and Others), Cause ( Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Route of Administration (Parenteral, Oral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific Industry Trends and Forecast to 2030
Overview of Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Treatment Market Dynamics
Driver
• Increasing prevalence and incidence of acute lung injury in the market
Restraint
• High cost of device and treatment
Opportunity
• Strategic initiatives joined with new product launches by market players
Market Players
Some of the major market players operating in the Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) market are listed below:
• Gilead Sciences, Inc.
• Terumo Medical Corporation
• Getinge AB.
• LivaNova PLC
• Medtronic
• ResMed
• Fisher & Paykel Healthcare Limited.
• Drägerwerk AG & Co. KGaA
• NIPRO
• Fresenius SE & Co. KGaA
• Hamilton Medical
• Pfizer Inc.
• WEINMANN Emergency Medical Technology GmbH + Co. KG
• EUROSETS
• Armstrong Medical
• nice Neotech Medical Systems Pvt. Ltd.
• Besmed Health Business Corp.
Table of Contents
1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW OF ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 22
1.4 LIMITATIONS 24
1.5 MARKETS COVERED 24
2 MARKET SEGMENTATION 26
2.1 MARKETS COVERED 26
2.2 GEOGRAPHICAL SCOPE 27
2.3 YEARS CONSIDERED FOR THE STUDY 28
2.4 CURRENCY AND PRICING 28
2.5 DBMR TRIPOD DATA VALIDATION MODEL 29
2.6 MULTIVARIATE MODELLING 32
2.7 TYPE LIFELINE CURVE 32
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 33
2.9 DBMR MARKET POSITION GRID 34
2.10 MARKET END USER COVERAGE GRID 35
2.11 VENDOR SHARE ANALYSIS 36
2.12 SECONDARY SOURCES 37
2.13 ASSUMPTIONS 37
3 EXECUTIVE SUMMARY 38
4 PREMIUM INSIGHTS 41
4.1 PESTEL ANALYSIS 42
4.2 PORTER’S FIVE FORCES 43
4.3 INSURANCE REIMBURSEMENT 44
4.3.1 CENTER FOR MEDICARE SERVICES (CMS)-ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION) 44
4.3.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION 44
4.3.3 ABBOTT CODING GUIDE FOR ECMO 45
4.3.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS) 45
4.3.5 CERN HEALTH INSURANCE SCHEME 46
4.3.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) - (MEDICARE & MEDICAID) 46
4.3.7 AMERICAN HOSPITAL ASSOCIATION 47
4.4 PIPELINE ANALYSIS 48
4.5 PRICING ANALYSIS 50
5 MARKET OVERVIEW 51
5.1 DRIVERS 53
5.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 53
5.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS TREATMENT 53
5.1.3 RISING RATE OF AIR POLLUTION AND UNHEALTHY LIFESTYLE 54
5.1.4 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 54
5.2 RESTRAINTS 55
5.2.1 COMPLICATIONS ASSOCIATED WITH THE TREATMENT 55
5.2.2 HIGH COST OF DEVICES AND TREATMENT 55
5.3 OPPORTUNITIES 56
5.3.1 RISING HEALTHCARE EXPENDITURE TO IMPROVE TREATMENT FACILITIES 56
5.3.2 STRATEGIC INITIATIVES JOINED WITH NEW PRODUCT LAUNCH BY MARKET PLAYERS 56
5.3.3 IMPROVING AWARENESS REGARDING ARD SYNDROME 57
5.4 CHALLENGES 58
5.4.1 STRINGENT RULES & REGULATIONS 58
5.4.2 MULTIPLE CHALLENGES FACED BY ICU STAFF 59
6 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE 60
6.1 OVERVIEW 61
6.2 MECHANICAL VENTILATION 64
6.2.1 HIGH-FLOW NASAL O2 65
6.2.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 65
6.2.3 CONTINUOUS POSITIVE AIRWAY PRESSURE 65
6.2.4 PRONE POSITION VENTILATION 65
6.2.5 OTHERS 66
6.3 CORTICOSTEROIDS 66
6.3.1 METHYLPREDNISOLONE 67
6.3.2 DEXAMETHASONE 67
6.3.3 OTHERS 67
6.4 ANTIVIRAL MEDICATION 68
6.4.1 RIBAVIRIN 69
6.4.2 OSELTAMIVIR 69
6.4.3 OTHERS 69
6.5 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 69
6.6 TOCILIZUMAB 70
6.7 OTHERS 70
7 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE 71
7.1 OVERVIEW 72
7.2 SEPSIS 75
7.3 INHALATION OF HARMFUL SUBSTANCES 75
7.4 SEVERE PNEUMONIA 76
7.5 OTHERS 76
8 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 77
8.1 OVERVIEW 78
8.2 PARENTERAL 81
8.2.1 INTRAVENOUS 81
8.2.2 INTRAMUSCULAR 81
8.3 ORAL 82
8.4 OTHERS 82
9 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER 83
9.1 OVERVIEW 84
9.2 HOSPITALS 87
9.3 SPECIALTY CLINICS 87
9.4 HOME HEALTHCARE 88
9.5 OTHERS 88
10 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 89
10.1 OVERVIEW 90
10.2 DIRECT TENDER 93
10.3 HOSPITAL PHARMACY 93
10.4 RETAIL PHARMACY 94
10.5 ONLINE PHARMACY 94
11 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION 95
11.1 ASIA-PACIFIC 97
11.1.1 JAPAN 103
11.1.2 CHINA 108
11.1.3 INDIA 113
11.1.4 SOUTH KOREA 118
11.1.5 AUSTRALIA 123
11.1.6 SINGAPORE 128
11.1.7 THAILAND 133
11.1.8 MALAYSIA 138
11.1.9 INDONESIA 143
11.1.10 PHILIPPINES 148
11.1.11 REST OF ASIA-PACIFIC 153
12 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, COMPANY LANDSCAPE 154
12.1 COMPANY SHARE ANALYSIS: ASIA - PACIFIC 154
13 SWOT ANALYSIS 155
14 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT, CPS 156
14.1 GILEAD SCIENCES INC 156
14.1.1 COMPANY SNAPSHOT 156
14.1.2 REVENUE ANALYSIS 157
14.1.3 COMPANY SHARE ANALYSIS 157
14.1.4 PRODUCT PORTFOLIO 158
14.1.5 RECENT DEVELOPMENT 158
14.2 TERUMO CORPORATION 159
14.2.1 COMPANY SNAPSHOT 159
14.2.2 REVENUE ANALYSIS 159
14.2.3 COMPANY SHARE ANALYSIS 160
14.2.4 PRODUCT PORTFOLIO 160
14.2.5 RECENT DEVELOPMENT 160
14.3 GETINGE 161
14.3.1 COMPANY SNAPSHOT 161
14.3.2 REVENUE ANALYSIS 161
14.3.3 COMPANY SHARE ANALYSIS 162
14.3.4 PRODUCT PORTFOLIO 162
14.3.5 RECENT DEVELOPMENT 162
14.4 LIVANOVA PLC 163
14.4.1 COMPANY SNAPSHOT 163
14.4.2 REVENUE ANALYSIS 163
14.4.3 COMPANY SHARE ANALYSIS 164
14.4.4 PRODUCT PORTFOLIO 164
14.4.5 RECENT DEVELOPMENTS 164
14.5 MEDTRONIC 165
14.5.1 COMPANY SNAPSHOT 165
14.5.2 REVENUE ANALYSIS 165
14.5.3 COMPANY SHARE ANALYSIS 166
14.5.4 PRODUCT PORTFOLIO 166
14.5.5 RECENT DEVELOPMENTS 166
14.6 ARMSTRONG MEDICAL 167
14.6.1 COMPANY SNAPSHOT 167
14.6.2 PRODUCT PORTFOLIO 167
14.6.3 RECENT DEVELOPMENT 167
14.7 BESMED HEALTH BUSINESS CORP 168
14.7.1 COMPANY SNAPSHOT 168
14.7.2 PRODUCT PORTFOLIO 168
14.7.3 RECENT DEVELOPMENTS 169
14.8 DRÄGERWERK AG & CO. KGAA 170
14.8.1 COMPANY SNAPSHOT 170
14.8.2 REVENUE ANALYSIS 170
14.8.3 PRODUCT PORTFOLIO 171
14.8.4 RECENT DEVELOPMENTS 171
14.9 EUROSETS 172
14.9.1 COMPANY SNAPSHOT 172
14.9.2 PRODUCT PORTFOLIO 172
14.9.3 RECENT DEVELOPMENT 172
14.10 FISHER & PAYKEL HEALTHCARE LIMITED 173
14.10.1 COMPANY SNAPSHOT 173
14.10.2 REVENUE ANALYSIS 173
14.10.3 PRODUCT PORTFOLIO 174
14.10.4 RECENT DEVELOPMENTS 174
14.11 FRESENIUS SE & CO. KGAA 175
14.11.1 COMPANY SNAPSHOT 175
14.11.2 REVENUE ANALYSIS 175
14.11.3 PRODUCT PORTFOLIO 176
14.11.4 RECENT DEVELOPMENT 176
14.12 HAMILTON MEDICAL 177
14.12.1 COMPANY SNAPSHOT 177
14.12.2 PRODUCT PORTFOLIO 177
14.12.3 RECENT DEVELOPMENT 177
14.13 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD 178
14.13.1 COMPANY SNAPSHOT 178
14.13.2 PRODUCT PORTFOLIO 178
14.13.3 RECENT DEVELOPMENT 178
14.14 NIPRO 179
14.14.1 COMPANY SNAPSHOT 179
14.14.2 REVENUE ANALYSIS 179
14.14.3 PRODUCT PORTFOLIO 180
14.14.4 RECENT DEVELOPMENT 180
14.15 PFIZER INC 181
14.15.1 COMPANY SNAPSHOT 181
14.15.2 REVENUE ANALYSIS 181
14.15.3 PRODUCT PORTFOLIO 182
14.15.4 RECENT DEVELOPMENT 182
14.16 RESMED 183
14.16.1 COMPANY SNAPSHOT 183
14.16.2 REVENUE ANALYSIS 183
14.16.3 PRODUCT PORTFOLIO 184
14.16.4 RECENT DEVELOPMENT 184
14.17 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG 185
14.17.1 COMPANY SNAPSHOT 185
14.17.2 PRODUCT PORTFOLIO 185
14.17.3 RECENT DEVELOPMENT 185
15 QUESTIONNAIRE 186
16 RELATED REPORTS 189